The abortifacient effect of 16,16-dimethyl-trans-delta 2-PGE1 methyl ester, a new prostaglandin analogue, on mid-trimester pregnancies and long-term follow-up observations.
The present clinical trials revealed that 16,16-Dimethyl-trans-delta 2-PGE1 methyl ester in the form of vaginal suppositories is highly effective in inducing mid-trimester termination of pregnancies. It also showed that prior treatment with laminaria and metreurynter may enhance the success rate while reducing the incidence and severity of side effects. It is easy and safe to use clinically, with minimal side effects, and in our series, revealed no deleterious effects on ensuing reproductive physiology. However, the definite mechanism involved in the action of this new analogue to cause myometrial contractions is still not completely understood, and requires further intensive investigation.
D000028:Abortion, Induced; D000527:Alprostadil / Q000031:analogs & derivatives*; D000818:Animals; D004106:Dilatation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D011247:Pregnancy; D011263:Pregnancy Trimester, Third; D011459:Prostaglandins E, Synthetic / Q000008:administration & dosage; D051381:Rats; D013488:Suppositories; D013997:Time Factors; D014590:Uterine Contraction / Q000187:drug effects; D014621:Vagina
D011459:Prostaglandins E, Synthetic; D013488:Suppositories; C021182:gemeprost; D000527:Alprostadil